Tarsa picks up $10M to get its osteoporosis pill to the FDA

Philadelphia's Tarsa Therapeutics has nailed down a $10 million credit facility to help bankroll an FDA submission for Ostora, the company's treatment for postmenopausal osteoporosis. The money, courtesy of Oxford Finance and Square 1 Bank, will help get Tarsa's lead drug in the hands of regulators, and the biotech expects to file its application in early 2015. In a Phase III trial, the drug proved itself superior to both placebo and nasal calcitonin spray in improving bone density at 48 weeks, Tarsa said. More

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.